Analysts at Stifel Nicolaus Didn’t Change their Past ‘Buy’ rating on Shares Akcea Therapeutics Inc (NASDAQ:AKCA), Set a $19.0 Target

January 22, 2018 - By Michael Collier

 Analysts at Stifel Nicolaus Didn't Change their Past ‘Buy’ rating on Shares Akcea Therapeutics Inc (NASDAQ:AKCA), Set a $19.0 Target

Akcea Therapeutics Inc (NASDAQ:AKCA) Rating Reaffirmed

The financial company has just set a TP of $19.0 on Akcea Therapeutics Inc (NASDAQ:AKCA) shares. This is 6.15 % from the previous stock close. In an analyst note revealed on Tuesday, 31 October, Stifel Nicolaus kept their Buy rating on shares of AKCA.

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Ratings Coverage

Among 3 analysts covering Akcea Therapeutics Inc (NASDAQ:AKCA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akcea Therapeutics Inc has $2500 highest and $19.0 lowest target. $22.50’s average target is 25.70% above currents $17.9 stock price. Akcea Therapeutics Inc had 5 analyst reports since August 8, 2017 according to SRatingsIntel. Stifel Nicolaus initiated the stock with “Buy” rating in Tuesday, August 8 report. The rating was maintained by Stifel Nicolaus on Tuesday, November 7 with “Buy”. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, October 31. The stock of Akcea Therapeutics, Inc. (NASDAQ:AKCA) earned “Buy” rating by BMO Capital Markets on Tuesday, August 8.

The stock increased 0.51% or $0.09 during the last trading session, reaching $17.9. About 244,906 shares traded. Akcea Therapeutics, Inc. (NASDAQ:AKCA) has 0.00% since January 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Akcea Therapeutics, Inc. (NASDAQ:AKCA) to report earnings on February, 5. After $-0.18 actual earnings per share reported by Akcea Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.11 % negative EPS growth.

Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company has market cap of $1.19 billion. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. It currently has negative earnings. The firm also develops AKCEA-APO-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides.

More notable recent Akcea Therapeutics, Inc. (NASDAQ:AKCA) news were published by: Seekingalpha.com which released: “Akcea Therapeutics Provides Update To IPO Plans” on May 10, 2017, also Seekingalpha.com with their article: “Akcea, A Wholly Owned Subsidiary Of Ionis Pharmaceutical, Set To IPO” published on June 27, 2017, Marketwatch.com published: “Akcea Therapeutics prices IPO below expected range” on July 13, 2017. More interesting news about Akcea Therapeutics, Inc. (NASDAQ:AKCA) were released by: Streetinsider.com and their article: “Akcea Therapeutics (AKCA) Names Michael MacLean as CFO” published on September 05, 2017 as well as Streetinsider.com‘s news article titled: “Akcea Therapeutics (AKCA) Commences Phase 2b Study of AKCEA-APOCIII-LRx in …” with publication date: January 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.